1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Benign Prostate Hyperplasia (BPH) Devices Market
Outlook
5.1. Market Size &
Forecast
5.1.1. By Value
5.2. Market Share &
Forecast
5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase
Inhibitors, and Phosphodiesterase-5 Inhibitors)
5.2.2. By Surgical Treatment (Transurethral resection of the
prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral
microwave Technique (TUMT), Transurethral needle ablation of the prostate
(TUNA), and others (Rezum therapy, Urolift therapy, etc)
5.2.3. By End User (hospitals and clinics, ambulatory surgical Centers,
and Others)
5.2.4. By Region (North America, Europe, Asia Pacific, South
America, Middle East & Africa)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Drug Treatment
5.3.2. By Surgical Treatment
5.3.3. By End User
5.3.4. By Region
6.
North America Benign Prostate Hyperplasia (BPH) Devices
Market Outlook
6.1. Market Size &
Forecast
6.1.1. By Value
6.2. Market Share &
Forecast
6.2.1. By Drug Treatment
6.2.2. By Surgical Treatment
6.2.3. By End User
6.2.4. By Country
6.3. By Region North
America: Country Analysis
6.3.1. United States Benign
Prostate Hyperplasia (BPH) Devices Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Drug Treatment
6.3.1.2.2.
By Surgical Treatment
6.3.1.2.3.
By End User
6.3.2. Canada Benign
Prostate Hyperplasia (BPH) Devices Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Drug Treatment
6.3.2.2.2.
By Surgical Treatment
6.3.2.2.3.
By End User
6.3.3. Mexico Benign
Prostate Hyperplasia (BPH) Devices Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Drug Treatment
6.3.3.2.2.
By Surgical Treatment
6.3.3.2.3.
By End User
7. Europe Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share &
Forecast
7.2.1. By Drug Treatment
7.2.2. By Surgical
Treatment
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country
Analysis
7.3.1.
France Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Treatment
7.3.1.2.2.
By Surgical Treatment
7.3.1.2.3.
By End User
7.3.2.
Germany Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Treatment
7.3.2.2.2.
By Surgical Treatment
7.3.2.2.3.
By End User
7.3.3.United Kingdom Benign
Prostate Hyperplasia (BPH) Treatment Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Drug Treatment
7.3.3.2.2.
By Surgical Treatment
7.3.3.2.3.
By End User
7.3.4.
Italy Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Drug Treatment
7.3.4.2.2.
By Surgical Treatment
7.3.4.2.3.
By End User
7.3.5.
Spain Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Drug Treatment
7.3.5.2.2.
By Surgical Treatment
7.3.5.2.3.
By End User
8.
Asia-Pacific Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
8.1. Market Size &
Forecast
8.1.1. By Value
8.2. Market Share &
Forecast
8.2.1. By Drug Treatment
8.2.2. By Surgical
Treatment
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific:
Country Analysis
8.3.1.
China Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Treatment
8.3.1.2.2.
By Surgical Treatment
8.3.1.2.3.
By End User
8.3.2.
Japan Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Treatment
8.3.2.2.2.
By Surgical Treatment
8.3.2.2.3.
By End User
8.3.3.
India Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Treatment
8.3.3.2.2.
By Surgical Treatment
8.3.3.2.3.
By End User
8.3.4.
South Korea Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Drug Treatment
8.3.4.2.2.
By Surgical Treatment
8.3.4.2.3.
By End User
8.3.5.
Australia Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Drug Treatment
8.3.5.2.2.
By Surgical Treatment
8.3.5.2.3.
By End User
9.
South America Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share &
Forecast
9.2.1. By Drug Treatment
9.2.2. By Surgical
Treatment
9.2.3. By End User
9.2.4. By Country
9.3. South America:
Country Analysis
9.3.1.
Brazil Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Treatment
9.3.1.2.2.
By Surgical Treatment
9.3.1.2.3.
By End User
9.4. Argentina Benign Prostate
Hyperplasia (BPH) Treatment Market Outlook
9.4.1.1.
Market Size & Forecast
9.4.1.1.1.
By Value
9.4.1.2.
Market Share & Forecast
9.4.1.2.1.
By Drug Treatment
9.4.1.2.2.
By Surgical Treatment
9.4.1.2.3.
By End User
9.5. Colombia Benign
Prostate Hyperplasia (BPH) Treatment Market Outlook
9.5.1.1.
Market Size & Forecast
9.5.1.1.1.
By Value
9.5.1.2.
Market Share & Forecast
9.5.1.2.1.
By Drug Treatment
9.5.1.2.2.
By Surgical Treatment
9.5.1.2.3.
By End User
10.
Middle East and Africa Benign Prostate Hyperplasia (BPH)
Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Drug Treatment
10.2.2. By Surgical
Treatment
10.2.3. By End User
10.2.4. By Country
10.3.
MEA: Country Analysis
10.3.1.
UAE Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
10.3.1.1. Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Drug Treatment
10.3.1.2.2.
By Surgical Treatment
10.3.1.2.3.
By End User
10.3.2.
Saudi Arabia Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
10.3.2.1. Market Size &
Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share &
Forecast
10.3.2.2.1.
By Drug Treatment
10.3.2.2.2.
By Surgical Treatment
10.3.2.2.3.
By End User
10.3.3.
South Africa Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share &
Forecast
10.3.3.2.1.
By Drug Treatment
10.3.3.2.2.
By Surgical Treatment
10.3.3.2.3.
By End User
10.3.4.
Turkey Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
10.3.4.1. Market Size &
Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share &
Forecast
10.3.4.2.1.
By Drug Treatment
10.3.4.2.2.
By Surgical Treatment
10.3.4.2.3.
By End User
10.3.5.
Egypt Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
10.3.5.1. Market Size &
Forecast
10.3.5.1.1.
By Value
10.3.5.2. Market Share &
Forecast
10.3.5.2.1.
By Drug Treatment
10.3.5.2.2.
By Surgical Treatment
10.3.5.2.3.
By End User
11. Market Dynamics
11.1.
Drivers
11.1.1. Increasing prevalence of Benign Prostate Hyperplasia
11.1.2. Growing geriatric population
11.1.3. Technological Advancement
11.2.
Challenges
11.2.1. High Cost of
Procedure
11.2.2. Side effects
associated with the technique
11.2.3. Lack of Skilled
Professionals to conduct invasive surgeries
12. Market Trends &
Developments
12.1.
Development of new drugs
12.2.
Development of new surgeries
13.
Clinical Trial Analysis
13.1.
Ongoing Clinical Trials
13.2.
Completed Clinical Trials
13.3.
Terminated Clinical Trials
13.4.
Breakdown of Pipeline, By Development Phase
13.5.
Breakdown of Pipeline, By Status
13.6.
Breakdown of Pipeline, By Study Type
13.7.
Breakdown of Pipeline, By Region
13.8.
Clinical Trials Heat Map
14. Competitive
Landscape
14.1.
Business Overview
14.2.
Product Offerings
14.3.
Recent Developments
14.4.
Financials (In Case of Listed Companies)
14.5.
Key Personnel
14.5.1. Boston Scientific
Corporation
14.5.2. Coloplast Corporation
14.5.3. Teleflex Incorporated
14.5.4. Olympus Corporation
14.5.5. Glaxo Smith Kline
PLC
14.5.6. Eli Lily
14.5.7. Abott Laboratories
14.5.8. Medifocus Inc.
14.5.9. Urologix, LLC
14.5.10. Pfizer Inc
15. Strategic Recommendations
16. About Us and Disclaimer